Drug intelligence / Profile preview

GPR-001

Development stage: Preclinical
Lead developer: Omic
Modality: Small Molecules

Overview

GPR-001 is a small molecule modulator of the G protein-coupled receptor 55 (GPR55) currently in the lead optimization stage of development by Omic Analytics. The drug is being developed for the treatment of inflammatory pain and sickle-cell vaso-occlusive crisis (VOC). By targeting GPR55, a receptor implicated in pain signaling and inflammatory processes, GPR-001 aims to provide a novel therapeutic approach for managing acute and chronic pain conditions as well as the severe complications associated with sickle cell disease.

Other names: GPR-001GPR001GPR 001

Targets

GPR55 (G protein-coupled receptor 55)

Beyond the preview

Go deeper on GPR-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPR-001.

Explore the full profile